- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer (NSCLC)
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 1469KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 189KB)
Nivolumab and ipilimumab – November 2020
Nivolumab and Ipilimumab; Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL Opdivo®; Ipilimumab: Injection concentrate for I.V. infusion 50 mg in 10 mL Yervoy®
Last updated
5 March 2021